<?xml version='1.0' encoding='utf-8'?>
<document id="26507723"><sentence text="The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers."><entity charOffset="14-24" id="DDI-PubMed.26507723.s1.e0" text="Nizatidine" /><entity charOffset="104-113" id="DDI-PubMed.26507723.s1.e1" text="Metformin" /><pair ddi="false" e1="DDI-PubMed.26507723.s1.e0" e2="DDI-PubMed.26507723.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26507723.s1.e0" e2="DDI-PubMed.26507723.s1.e1" /></sentence><sentence text="In the proximal tubule, basic drugs are transported from the renal cells to the tubule lumen through the concerted action of the H(+)/organic cation antiporters, multidrug and toxin extrusion (MATE) 1 and MATE2K" /><sentence text=" Dual inhibitors of the MATE transporters have been shown to have a clinically relevant effect on the pharmacokinetics of concomitantly administered basic drugs" /><sentence text=" However, the clinical impact of selective renal organic cation transport inhibition on the pharmacokinetics and pharmacodynamics of basic drugs, such as metformin, is unknown"><entity charOffset="154-163" id="DDI-PubMed.26507723.s4.e0" text="metformin" /></sentence><sentence text=" This study sought to identify a selective MATE2K inhibitor in vitro and to determine its clinical impact on the pharmacokinetics and pharmacodynamics of metformin in healthy subjects"><entity charOffset="154-163" id="DDI-PubMed.26507723.s5.e0" text="metformin" /></sentence><sentence text="" /><sentence text="Strategic cell-based screening of 71 US Food and Drug Administration (FDA)-approved medications was conducted to identify selective inhibitors of renal organic cation transporters that are capable of inhibiting at clinically relevant concentrations" /><sentence text=" From this screen, nizatidine was identified and predicted to be a clinically potent and selective inhibitor of MATE2K-mediated transport"><entity charOffset="19-29" id="DDI-PubMed.26507723.s8.e0" text="nizatidine" /></sentence><sentence text=" The effect of nizatidine on the pharmacokinetics and pharmacodynamics of metformin was evaluated in 12 healthy volunteers in an open-label, randomized, two-phase crossover drug-drug interaction (DDI) study"><entity charOffset="15-25" id="DDI-PubMed.26507723.s9.e0" text="nizatidine" /><entity charOffset="74-83" id="DDI-PubMed.26507723.s9.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.26507723.s9.e0" e2="DDI-PubMed.26507723.s9.e0" /><pair ddi="false" e1="DDI-PubMed.26507723.s9.e0" e2="DDI-PubMed.26507723.s9.e1" /></sentence><sentence text="" /><sentence text="In healthy volunteers, the MATE2K-selective inhibitor nizatidine significantly increased the apparent volume of distribution, half-life, and hypoglycemic activity of metformin"><entity charOffset="54-64" id="DDI-PubMed.26507723.s11.e0" text="nizatidine" /><entity charOffset="166-175" id="DDI-PubMed.26507723.s11.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.26507723.s11.e0" e2="DDI-PubMed.26507723.s11.e0" /><pair ddi="false" e1="DDI-PubMed.26507723.s11.e0" e2="DDI-PubMed.26507723.s11.e1" /></sentence><sentence text=" However, despite achieving unbound maximum concentrations greater than the in vitro inhibition potency (concentration of drug producing 50% inhibition [IC50]) of MATE2K-mediated transport, nizatidine did not affect the renal clearance (CLR) or net secretory clearance of metformin"><entity charOffset="190-200" id="DDI-PubMed.26507723.s12.e0" text="nizatidine" /><entity charOffset="272-281" id="DDI-PubMed.26507723.s12.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.26507723.s12.e0" e2="DDI-PubMed.26507723.s12.e0" /><pair ddi="false" e1="DDI-PubMed.26507723.s12.e0" e2="DDI-PubMed.26507723.s12.e1" /></sentence><sentence text="" /><sentence text="This study demonstrates that a selective inhibition of MATE2K by nizatidine affected the apparent volume of distribution, tissue concentrations, and peripheral effects of metformin"><entity charOffset="65-75" id="DDI-PubMed.26507723.s14.e0" text="nizatidine" /><entity charOffset="171-180" id="DDI-PubMed.26507723.s14.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.26507723.s14.e0" e2="DDI-PubMed.26507723.s14.e0" /><pair ddi="false" e1="DDI-PubMed.26507723.s14.e0" e2="DDI-PubMed.26507723.s14.e1" /></sentence><sentence text=" However, nizatidine did not alter systemic concentrations or the CLR of metformin, suggesting that specific MATE2K inhibition may not be sufficient to cause renal DDIs with metformin"><entity charOffset="10-20" id="DDI-PubMed.26507723.s15.e0" text="nizatidine" /><entity charOffset="73-82" id="DDI-PubMed.26507723.s15.e1" text="metformin" /><entity charOffset="174-183" id="DDI-PubMed.26507723.s15.e2" text="metformin" /><pair ddi="false" e1="DDI-PubMed.26507723.s15.e0" e2="DDI-PubMed.26507723.s15.e0" /><pair ddi="false" e1="DDI-PubMed.26507723.s15.e0" e2="DDI-PubMed.26507723.s15.e1" /><pair ddi="false" e1="DDI-PubMed.26507723.s15.e0" e2="DDI-PubMed.26507723.s15.e2" /><pair ddi="false" e1="DDI-PubMed.26507723.s15.e1" e2="DDI-PubMed.26507723.s15.e1" /><pair ddi="false" e1="DDI-PubMed.26507723.s15.e1" e2="DDI-PubMed.26507723.s15.e2" /></sentence><sentence text="" /></document>